Variable Wild-type SARS-CoV-2 convalescents Unvaccinated Omicron convalescents Vaccinated Omicron convalescents
Number of participants 20 5 27
Age (years), median (range) 53 (17-79) 40 (34-43) 29 (25-54)
Sex at birth, female 10 (50%) 3 (60%) 19 (70%)
COVID vaccination history
Two-dose inactivated vaccines 0 N/A 1 (3.7%)
Three-dose inactivated vaccines 0 N/A 18 (66.7%)
Two-dose Ad5-nCoV (adenovirus vector vaccine)
0
N/A
6 (22.2%)
Three-dose Recombinant Fusion Protein vaccines
0
N/A
1 (3.7%)
Two-dose inactivated vaccines plus one-dose Ad5-nCoV
0
N/A
1 (3.7%)
COVID disease severity
Asymptomatic 0 1 (20%) 0
Mild 4 (20%) 4 (80%) 19 (70%)
Moderate 9 (45%) 0 8 (30%)
Severe 4 (20%) 0 0
Critical 3 (15%) 0 0
Time between last vaccination and confirmed infection N/A N/A 6-22 months
Time between infection and serum sampling when SARS-CoV-2 negative 2-8 weeks 3-5 weeks 2-9 weeks
Method of SARS-CoV-2 testing
Quantitative PCR 20 (100%) 1 (20%) 5 (19%)
Rapid antigen detection 0 4 (80%) 22 (81%)